MML Investors Services
RARE icon

MML Investors Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

MML Investors Services’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,112
Closed -$240K – 1933
2021
Q1 		$240K Buy
2,112
+35
+2% +$4.76K ﹤0.01% 1631
2020
Q4 		$288K Buy
+2,077
New +$246K ﹤0.01% 1413

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MML Investors Services's RARE Position: Q2 2021 in Review

MML Investors Services sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 2,112 shares — an estimated $240K sold.

MML Investors Services first reported a position in RARE in Q4 2020 and held it in 2 quarters. The position peaked at $288K in Q4 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

  • MML Investors Services reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • MML Investors Services sold 2,112 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $240K.
  • MML Investors Services first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 2 quarters.
  • MML Investors Services's Ultragenyx Pharmaceutical position peaked at $288K in Q4 2020.
  • 241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on MML Investors Services's 13F filing for Q2 2021, filed 13 Aug 2021.